ANAB Stock Analysis: Buy, Sell, or Hold?
ANAB - AnaptysBio, Inc. Common Stock
$55.67
-1.73 (-3.01%)
▼
5d:
-11.24%
30d:
+1.13%
90d:
+11.12%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 04, 2026
Smart Money Accumulation
ANAB is down 11.3% this week, but smart money is accumulating calls. Top strike: $65 2026-05-15 with 16 OI. Call ratio: 96% View Scanner →
Strength: 10.0/10
Get Alerted When ANAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ANAB is down 11.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ANAB is down 11.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ANAB is currently trading at $55.67, which is considered fair relative to its 30-day fair value range of $55.00 to $64.14.
Technical Outlook: Technically, ANAB is in a strong uptrend. The price is currently testing key support at $55.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $78.25 (+36.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANAB is in a strong uptrend. The price is currently testing key support at $55.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $78.25 (+36.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$55.00 -
$64.14
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 36.3% below Wall St target ($78.25)
- WARNING: Recommendation downgraded due to -11.2% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$55.00 -
$64.14
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$55.23
Resistance Level
$68.39
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.16
Wall Street Target
$78.25
(+36.3%)
Revenue Growth (YoY)
151.1%
Profit Margin
-5.6%
Share & Embed Analysis
Last updated: March 30, 2026 3:24 PM ET
Data refreshes hourly during market hours. Next update: 4:24 PM
Data refreshes hourly during market hours. Next update: 4:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric J Loumeau
SELL
10000 shares
2026-02-11
Magda Marquet
SELL
11000 shares
2026-01-15
Daniel Faga
SELL
14281 shares
2026-01-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 48 HOLD |